Levi & Korsinsky has started an investigation into Prestige Consumer Healthcare following the company's Q4 earnings miss and an undisclosed $150 million acquisition of Australian firm LaCorium. Prestige had projected a 57% adjusted gross margin and $245 million free cash flow for the year, but reported 55.4% margin and $228 million cash flow, missing internal forecasts. The acquisition was not mentioned during the Q3 earnings call or in forward guidance, leading to a sharp decline in Prestige's stock. Investors who suffered losses may seek recovery under federal securities laws as the investigation proceeds.
Anthony Scaramucci criticized the US decision to grant China permanent trade relations and WTO membership, saying it allowed China to protect its economy while exporting freely to the US. He argued that China used this advantage to take US technology...
Novo Nordisk is preparing to launch its Wegovy weight-loss pill outside the U.S. later this year, targeting major international markets like the UK, Germany, and Denmark. The company sees a significant opportunity to expand globally, leveraging teleh...
Sohu.com Limited reported Q1 2026 revenues of $141 million, up 4% year-over-year, driven mainly by a 6% increase in online game revenues to $125 million. However, marketing services revenue declined 8% year-over-year. The company posted a GAAP net lo...
HIVE Digital Technologies' subsidiary BUZZ is investing about CAD 3.5 billion to build one of Canada's largest AI gigafactories in the Greater Toronto Area, targeting completion in late 2027. The facility will have 320 MW of power capacity and host o...
REalloys is rated a Buy with a $19 price target due to its unique position as a vertically integrated US rare earth company covering all four supply chain stages. The company benefits from strong US policy support and rising demand outside China for ...
